Business Context and Reporting Period
Syndax Pharmaceuticals Inc. (SNDX), a Delaware corporation and emerging growth company, filed this Form 8-K on April 30, 2020. The report details the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 5,555,556 shares of common stock at a public price of $18.00 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 833,333 shares.
- Expected Net Proceeds: Approximately $93.7 million, or approximately $107.8 million if the over-allotment option is exercised in full.
- Underwriters: Citigroup Global Markets Inc. and Cowen and Company, LLC.
- Closing Date: Expected on or about May 4, 2020.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this is a current report focused on a capital raise event rather than a periodic financial statement.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of new shares. To support the offering, the Company and certain directors and executive officers have agreed to a 60-day lock-up period, prohibiting the sale or transfer of common stock without the written consent of the Representatives until June 29, 2020.
Outlook, Risks, and Management Commentary
The offering is being made pursuant to a shelf registration statement (File No. 333-233564) declared effective in September 2019. The closing of the transaction is subject to the satisfaction of customary closing conditions. The filing incorporates a press release regarding the pricing of the offering but does not contain specific forward-looking guidance on clinical trials or product development timelines within the text of this 8-K.
Investor Verification Checklist
- Verify the final closing date and whether the underwriters exercised the 833,333 share over-allotment option.
- Confirm the exact net proceeds received after deducting all underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Monitor the Company's cash position post-closing to assess runway for ongoing clinical development.